Harbi E, Aschner M (2025) Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. Mol Biol Rep 52(1):281

Article  CAS  PubMed  Google Scholar 

Kaelin WG (2017) Jr. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc 128:298–307

PubMed  PubMed Central  Google Scholar 

Acuña-Pilarte K, Koh MY (2025) The HIF axes in cancer: angiogenesis, metabolism, and immune-modulation. Trends Biochem Sci 50:677–694

Article  PubMed  Google Scholar 

Wettersten HI, Aboud OA, Lara PN et al (2017) Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol 13(7):410–419

Article  CAS  PubMed  Google Scholar 

Wallace EM, Rizzi JP, Han GA, Small-Molecule (2016) Antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma. Cancer Res 76(18):5491–5500

Article  CAS  PubMed  Google Scholar 

Courtney KD, Bezwada D, Mashimo T (2018) Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. Cell Metab 28(5):793–800e792

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Lazris D, Wong R, Tykodi SS (2025) Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol 17:17588359251317846

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palazon A, Goldrath AW, Nizet V et al (2014) HIF transcription factors, inflammation, and immunity. Immunity 41(4):518–528

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhuang J-j, Liu Q, Wu D-l et al (2022) Current strategies and progress for targeting the undruggable transcription factors. Acta Pharmacol Sin 43(10):2474–2481

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren X, Diao X, Zhuang J, Wu D (2022) Structural basis for the allosteric inhibition of hypoxia-inducible factor-2 by belzutifan. Mol Pharmacol 102:240–247

Article  CAS  Google Scholar 

Shaikat AH, Azad SMAK, Tamim MAR, Ullah MS, Amin MN, Sabbir MK (2025) Investigating hypoxia-inducible factor signaling in cancer: mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathog Ther 2:231–245

Google Scholar 

Shah SU et al (2024) Oral Hypoxia-Inducible factor 2α inhibitor Belzutifan in ocular von Hippel–Lindau disease: subgroup analysis of LITESPARK-004. Ophthalmology 131:1158–1166

Google Scholar 

Iliopoulos O, Iversen AB, Narayan V et al (2024) Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 25(10):1325–1336

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hazarika M et al (2022) FDA approval summary: Belzutifan for von Hippel–Lindau Disease–Associated tumors. Clin Cancer Res 28(22):4843–4849

Article  Google Scholar 

Jonasch E, Bauer TM, Papadopoulos KP et al (2024) Phase I LITESPARK-001 study of Belzutifan for advanced solid tumors: extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer 196:113434

Article  CAS  PubMed  Google Scholar 

Choueiri TK, McDermott DF, Merchan J et al (2023) Belzutifan plus Cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol 24(5):553–562

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Powles T, Peltola K et al (2024) Belzutifan versus everolimus for advanced Renal-Cell carcinoma. N Engl J Med 391(8):710–721

Article  CAS  PubMed  Google Scholar 

Rini BI, Suarez Rodriguez C, Albiges L et al (2024) LBA74 final analysis of the phase III LITESPARK-005 study of Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol 35:S1262–S1263

Article  Google Scholar 

Fallah J, Heiss BL, Joeng HK et al (2024) FDA approval summary: Belzutifan for patients with advanced renal cell carcinoma. Clin Cancer Res 30(22):5003–5008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Bauer TM, Merchan J et al (2025) Belzutifan plus Cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. Lancet Oncol 26(1):64–73

Article  CAS  Google Scholar 

Choi SH, Chen Y-W, Panian J et al (2025) Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma. Oncologist 30(3):oyae276

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Schmidinger M, Eto M et al (2023) LITESPARK-011: Belzutifan plus lenvatinib vs Cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol 19(2):113–121

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov (2025) NCT04736706 — Pembrolizumab + belzutifan + lenvatinib vs pembrolizumab + lenvatinib (LITESPARK-012)

Qiu J, Zhou J, Cai L et al (2025) Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: results of LITESPARK-015 study. American Society of Clinical Oncology

Canal A (2025) FDA Updates Highlighting the Latest Cancer Treatments. Oncology Times

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations [Internet] (2021) Available from: https://clinicaltrials.gov/study/NCT04924075

Dogra R, Vaishampayan U (2025) Hypoxia inducible Factor-2α (HIF-2α) pathway inhibitors. J Kidney Cancer VHL 12(3):1

Article  PubMed  PubMed Central  Google Scholar 

Strowd RE, De La Fuente MI, Bauer TM et al (2024) Phase 1 LITESPARK-001 study of Belzutifan in advanced solid tumors: results of the glioblastoma cohort. American Society of Clinical Oncology

Curry L, Soleimani M (2024) Belzutifan: a novel therapeutic for the management of von Hippel–Lindau disease and beyond. Future Oncol 20(18):1251–1266

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Bauer TM, Papadopoulos KP (2021) Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med 27(5):802–805

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Plimack ER, Bauer TM (2020) Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). American Society of Clinical Oncology

Song G, Xue S, Zhu Y et al (2024) The efficacy and safety of Belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis. BMC Pharmacol Toxicol 25(1):100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dogra R, Vaishampayan U (2025) Hypoxia-Inducible Factor-2α (HIF-2α) pathway inhibitors. J Kidney Cancer VHL 12(3):1–15

Article  PubMed  PubMed Central  Google Scholar 

Kucharczyk J, Bhatt A, Bauer L et al (2025) Belzutifan-Associated hypoxia: A review of the novel Therapeutic, proposed mechanisms of Hypoxia, and management recommendations. Int J Mol Sci 26(15):7094

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan X, Ruan W, Bobrow B et al (2024) Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat Rev Drug Discovery 23(3):175–200

Article  CAS  PubMed  Google Scholar 

Rioja P, Rey-Cardenas M, De Velasco G (2024) Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma. Cancer Treat Rev 129:102801

Article  CAS  PubMed  Google Scholar 

Ang SO, Chen H, Hirota K et al (2002) Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32(4):614–621

Article  CAS